For this venture, he is aiming to advance the technology to newborn diagnostic testing and eventually the screening market. He completed his post-doctoral fellowship at Dana Farber Cancer Institute/Harvard Medical School.Gabor brings over 20 years of expertise from both academia and industry in the areas of genomics, sales, and strategic business development.
Gabor holds a BS in Biochemistry from the University of Rochester and a Masters degree from Syracuse University.
Tanya brings over 12 years of proven leadership and development experience in whole genome and targeted resequencing to the creation of workflows and products that meet the specific needs of the newborn diagnostics market.
While at Applied Biosystems and Life Technologies she drove novel solutions from idea to launch for three NGS platforms.
Parabase Genomics’ is committed to improving neonatal care through the development of early diagnostics for actionable inherited disorders.
The company’s Newborn Dx Tests™ are designed to be rapid and less invasive, using dried blood spots, and incorporate the most damaging disorders.
Physicians can now make precise treatment decisions based on an individual’s molecular profile rather than severe symptomology.
Newborn Dx will assist neonatologists to make prompt and informed decisions while the patient is still in the hospital by matching them to the best treatment and clinical trial options.
The company’s advisors are world leaders in newborn medicine, genomic technologies and informatics. Mehlman has worked in the life sciences field since 1985 through medical school, operational positions, institutional investing and strategic consulting. Mehlman has specialized in investing in public and private life science related companies.
He initially managed the Essex Investment Management Global Life Science Fund and subsequently through his own company, Andesite, Inc.
He brings a depth of experience in medical diagnostics, most recently through an investment in a non-invasive prenatal testing company. Mehlman holds an MBA from the Harvard Business School.
Andy's early work at Agilent Technologies inspired him to develop and apply targeted next generation sequencing technologies in medical genetics. in Molecular Biology from the University of Minnesota and a Masters degree in Genetics and Statistics from the University of Saskatchewan.